Citations 2
Research Code Sharing in Support of Gold Standard Science
Klonoff, David C., Espinoza, Juan, Mader, Julia K., Heinemann, Lutz, Cobelli, Claudio, Kerr, David , Kovatchev, Boris, Najafi, Bijan , Prahalad, Priya , Zheng, Yaguang , Shao, Mandy M. , Scheideman, Agatha F. , DuNova, Ashley Y. , Kohn, Michael , Umpierrez, Guillermo E., Malek, Aiman Abdel, Agus, Michael S. D., Ahn, David T., AlSaad, Rawan , AL-SOFIANI, MOHAMMED, Armstrong, David, Arnold, Mark A., Bequette, B. Wayne , Bellazzi, Riccardo, Cengiz, Eda, Chase, J. Geoffrey, Chen, Jake Y. , Cichosz, Simon Lebech , Clements, Mark A. , Close, Kelly L., Cuadros, Jorge , Contreras, Ivan, Drincic, Andjela , Facchinetti, Andrea, Fleming, G. Alexander , Gabbay, Monica A. L., Healey, Elizabeth, Hoang, Thanh D., Kulzer, Bernhard, Belle, Jeff La, Lee, Aaron, Lee, Cecilia S., Lee, Wei-An , Liepmann, Dorian , Maahs, David M. , Mathioudakis, Nestoras, Metwally, Ahmed A., Mohan, Viswanathan, Moon, Sun-Joon, Raeder, Helge, Rhee, Connie, Rhee, Eun-Jung, Scheinker, David , Shah, Viral N., Snyder, Michael P., Sode, Koji, Spanakis, Elias K., Svensson, Jannet, Vaswani, Nitin, Vareth, Maryam, Wallia, Amisha , Wang, Tao, Williams, Ebonie, Wolf, Ruth, Wong, Jenise C., Yeshiwas, Sewagegn, Shah, Shahid N. , Cobelli, Claudio , Snyder, M , Kovatchev, Boris , Heinemann, Lutz , Espinoza, Juan , Mathioudakis, Nestoras , Mader, Julia K. , Klonoff, David C , Espinoza, Juan , Mader, Julia K , Heinemann, Lutz , Cobelli, Claudio , Kovatchev, Boris , Umpierrez, Guillermo E. , Wong, Tien Y , Abdel Malek, Aiman , Agus, Michael S D , Ahn, David T , AlSaad, Rawan , Al-Sofiani, Mohammed E , Armstrong, David , Arnold, Mark A , Bee, Yong Mong , Bequette, B Wayne , Bellazzi, Riccardo , Cengiz, Eda , Chase, James Geoffrey , Chen, Haipeng , Chen, Jake Y , Cichosz, Simon L , Cinar, Ali , Clements, Mark A , Close, Kelly L , Cuadros, Jorge , Contreras, Ivan , Datta, Gora , Dhatariya, Ketan , Doyle, Francis J , Drincic, Angela , Facchinetti, Andrea , Fleming, G Alexander , Foreman, Joshua , Gabbay, Monica A L , Gutierrez-Osuna, Ricardo , Healey, Elizabeth , Hoang, Thanh D , Jacobs, Peter G , Kulzer, Bernhard , La Belle, Jeff , Lee, Aaron Y , Lee, Cecilia S , Lee, Wei-An Andy , Liepmann, Dorian , Maahs, David M , Mathioudakis, Nestoras N , Meo, Sultan A , Metwally, Ahmed A , Misra, Shivani , Mohan, Viswanathan , Moon, Sun-Joon , Raeder, Helge , Rhee, Connie M , Rhee, Eun-Jung , Scheinker, David , Shah, Viral N , Sheng, Bin , Snyder, Michael , Sode, Koji , Spanakis, Elias K , Svensson, Jannet , Vaswani, Nitin , Vareth, Maryam , Vehi, Josep , Wallia, Amisha , Waki, Kayo , Wang, Tao , Williams, Eric , Wolf, Risa M , Wong, Jenise C , Bekele, Sewagegn Yeshiwas , Zilbermint, Mihail , Shah, Shahid N , Klonoff, David C. , DuBord, Ashley Y., Wong, Tien Yin , Agus, Michael S. D. , Ahn, David , Close, Kelly L. , Dhatariya, Ketan , Doyle, Francis J. , Rhee, Connie M. , Sode, Koji , Spanakis, Elias K. , Waki, Kayo , Wong, Jenise C. , Zilbermint, Mihail
Journal of Diabetes Science and Technology | January 14, 2026 | Volume: 20 | Issue: 3 | Pages: 609-619
Sharing research code in an open access version-controlled repository offers significant benefits for both science as a whole and for individual researchers. In this article, we focus on this practice, which is fully aligned with the NIH’s Gold Standard Science (GSS) program as well as FAIR (findable, accessible, interoperable, reusable) and TRUST (transparency, responsibility, user focus, sustainability, technology) principles. Gold Standard Science supports open science by emphasizing transparency, reproducibility, and the use of best practices that enable others to verify and extend research. Pairing a research article’s cited data snapshot with a versioned, environment-specific code release, deposited in a companion code repository, ensures that, upon submission to a medical journal, readers and reviewers can directly verify results. An executable and updatable companion code repository complements, rather than replaces, established research data repositories. When code underlying medical research results is made openly available, then other scientists can inspect, run, and validate analyses. These activities enhance reproducibility, which is a core aim of GSS. Shared code also facilitates collaborative innovation by allowing researchers to extend the utility of the code to new datasets and applications. For researchers, code sharing can increase visibility, credibility, and citation impact. Demonstrating transparency through shared executable and updatable code builds trust with journal readers, peer reviewers, funders, and peers. Shared code in an open access repository signals adherence to high standards of scientific integrity and attracts opportunities for collaboration. A researcher who shares code receives recognition as a leader in reproducible, trustworthy research consistent with NIH’s GSS principles.
Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial
Isganaitis, Elvira , Raghinaru, Dan, Ambler-Osborn, Louise, Pinsker, Jordan E. , Buckingham, Bruce A. , Ekhlaspour, Laya , Kudva, Yogish C., Forlenza, Gregory P. , Beck, Roy W., Kollman, Craig, Lum, John W. , Brown, Sue A. , Laffel, Lori M. , Kovatchev, Boris, Anderson, Stacey, Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Gondor-Fredrick, Linda, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Church, Mei Mei , André, Camille , Piper, Molly, Lam, David , O’Malley, Grenye , Levister, Camilla, Ogyaadu, Selassie, Lovett, Jessica, Simha, Vinaya , Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Alonso, G. Todd, Slover, Robert H., Jost, Emily , Berget, Cari, Towers, Lindsey, Rossick-Solis, Alex, Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Dassau, Eyal , Passman, Samantha, Campos, Tiffany, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Green, Neal, Laffel, Lori, Pinsker, Jordan, Doyle, Francis, Renard, Eric, Reznik, Yves , Lum, John, Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Green, Jennifer , Legault, Laurent , Wysham, Carol , Eggerman, Thomas, Forlenza, Gregory P , Buckingham, Bruce , Wadwa, R Paul , Kudva, Yogish C. , Levy, Carol J. , Kollman, Craig , Kovatchev, Boris , Anderson, Stacey M. , Oliveri, Mary Clancy , Kumari, Kanchan , Messer, Laurel H , Jacobson, Tali, Doyle, Francis J. , Patibandla, Nandan, Laffel, Lori M. , Cobelli, Claudio , Beck, Roy W. , Willi, Steven Matthew
Diabetes Technology & Therapeutics | November 20, 2020 | Volume: 23 | Issue: 5 | Pages: 342-349
Objective: To assess the efficacy and safety of closed-loop control (CLC) insulin delivery system in adolescents and young adults with type 1 diabetes. Research Design and Methods: Prespecified subanalysis of outcomes in adolescents and young adults aged 14–24 years old with type 1 diabetes in a previously published 6-month multicenter randomized trial. Participants were randomly assigned 2:1 to CLC (Tandem Control-IQ) or sensor augmented pump (SAP, various pumps+Dexcom G6 CGM) and followed for 6 months. Results: Mean age of the 63 participants was 17 years, median type 1 diabetes duration was 7 years, and mean baseline HbA1c was 8.1%. All 63 completed the trial. Time in range (TIR) increased by 13% with CLC versus decreasing by 1% with SAP (adjusted treatment group difference = +13% [+3.1 h/day]; 95% confidence interval [CI] 9–16, P < 0.001), which largely reflected a reduction in time >180 mg/dL (adjusted difference −12% [−2.9 h/day], P < 0.001). Time <70 mg/dL decreased by 1.6% with CLC versus 0.3% with SAP (adjusted difference −0.7% [−10 min/day], 95% CI −1.0% to −0.2%, P = 0.002). CLC use averaged 89% of the time for 6 months. The mean adjusted difference in HbA1c after 6 months was 0.30% in CLC versus SAP (95% CI −0.67 to +0.08, P = 0.13). There was one diabetic ketoacidosis episode in the CLC group. Conclusions: CLC use for 6 months was substantial and associated with improved TIR and reduced hypoglycemia in adolescents and young adults with type 1 diabetes. Thus, CLC has the potential to improve glycemic outcomes in this challenging age group. The clinical trial was registered with ClinicalTrials.gov (NCT03563313).